Efgartigimod in the treatment of Guillain-Barré syndrome: case report
Guillain–Barré syndrome (GBS) is a rare neurological disorder characterized by muscle weakness and paralysis. Although the exact etiology remains unclear, the current standard treatments include intravenous immunoglobulin (IVIG) and plasma exchange (PLEX) therapy. While the majority of GBS patients...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2025-09-01
|
| Серии: | Frontiers in Immunology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1586663/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|